Is transcatheter aortic valve replacement a profitable procedure in a high-volume French hospital?

Background. - Transcatheter aortic valve replacement (TAVR) has revolutionized the prognosis of inoperable patients with severe aortic valve stenosis. Yet, the implantation of expensive prostheses in patients with comorbidities may be questionable in an era when healthcare costs are becoming a major concern. Aim. - The objective of this study was to assess whether the TAVR procedure is profitable in a high-volume French hospital. Methods. - Consecutive patients eligible for transfemoral TAVR using the SAPIEN bioprostheses (Edwards Lifesciences, Irvine, CA, USA) were included retrospectively in this single-centre study between September 2014 and December 2015. Three medicoeconomic severity-level subgroups were considered. The primary clinical endpoint was the difference between hospital costs and revenues, calculated for each patient. Secondary composite endpoints included major adverse events within 30 days and breakdown of costs. Results. - Overall, 189 patients were included in the analysis. Three patients died (two from non-cardiac causes) within 30 days of the procedure. The mean hospital cost was (sic)27,530 +/- 3814 per patient, and the mean hospital income was (sic)30,313 +/- 2681 per patient (P<0.001), resulting in a significant profit of (sic)2783 +/- 1743 per patient. The total estimated profit was (sic)525,000 for the whole study period. The largest benefits were observed for patients assigned to the lowest severity level. The price of the bioprosthesis represented 71% of the total costs. Conclusions. - The TAVR procedure performed in carefully selected patients was profitable for the academic centre, regardless of the level of severity assigned to the patients. (C) 2018 Elsevier Masson SAS. All rights reserved.